Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 931 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Infection Clear all
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

NCT01992094
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years and older
Enrollment
2,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

NCT00662272
View directory record Official record
Conditions
Influenza
Interventions
Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
Biological
Lead sponsor
Colby Pharmaceutical Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age

NCT00128167
View directory record Official record
Conditions
Influenza
Interventions
Liquid CAIV-T
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
8,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
107
States / cities
Hoover, Alabama • Tuscaloosa, Alabama • Little Rock, Arkansas + 96 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

NCT02285998
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
9,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

H5 Booster After a Two Dose Schedule

NCT00240968
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 16, 2013 · Synced Oct 15, 2026, 1:16 AM EDT
Not listed Not applicable Interventional

Immunogenicity of Influenza Vaccine in Long Term Care

NCT02933723
View directory record Official record
Conditions
Influenza
Interventions
Blood Draw
Procedure
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Inactivated Influenza Via Jet Injection

NCT02290691
View directory record Official record
Conditions
Influenza, Human
Interventions
Influenza Vaccine
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
985 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
6
States / cities
Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 15, 2026, 1:16 AM EDT
Completed No phase listed Observational Results available

Collection and Testing of Respiratory Samples

NCT01302418
View directory record Official record
Conditions
QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
Interventions
artus Influenza A/B RT-PCR Test
Device
Lead sponsor
QIAGEN Gaithersburg, Inc
Industry
Eligibility
Not listed
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

NCT00755703
View directory record Official record
Conditions
Influenza A Subtype H5N1 Infection
Interventions
Pandemic Influenza Vaccine, Placebo
Biological
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
19 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets

NCT03898986
View directory record Official record
Conditions
Influenza
Interventions
Live attenuated influenza vaccine (LAIV4), Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 20 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Influenza Vaccination in Bone Marrow Transplantation

NCT00419224
View directory record Official record
Conditions
Influenza
Interventions
inactivated split-virus influenza vaccine
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 11, 2007 · Synced Oct 15, 2026, 1:16 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

NCT00335855
View directory record Official record
Conditions
Influenza
Interventions
Auto-injector for IM/SC vaccine administration
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2006
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

NCT01964989
View directory record Official record
Conditions
Influenza Virus
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 71 Months
Enrollment
10,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
91
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults

NCT05868382
View directory record Official record
Conditions
Influenza
Interventions
mRNA-1010, mRNA-1010.4, mRNA-1010.6
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
10
States / cities
Hollywood, Florida • Miami, Florida • Lenexa, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults

NCT01612000
View directory record Official record
Conditions
Influenza
Interventions
PanBlok, rHA adjuvant
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Omaha, Nebraska • Rochester, New York • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional

Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients

NCT01525004
View directory record Official record
Conditions
Pediatric Solid Organ Transplant Patients
Interventions
High-Dose trivalent inactivated influenza vaccine, Standard dose trivalent inactivated influenza vaccine
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
3 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults

NCT02258334
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent vaccine, 2014-2015 formulation, Fluzone I®ntradermal vaccine, 2014-2015 formulation, Fluzone High Dose vaccine, 2014-2015 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above

NCT07204964
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation B1), Flu mRNA (Formulation B3), Flu mRNA(Formulation A), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
971 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
15
States / cities
Guntersville, Alabama • Canoga Park, California • Walnut Creek, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 1:16 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
1,500,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 15, 2026, 1:16 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Influenza IMPRINT Cohort: Defining the Impact of Initial Influenza Exposure on Immunity in Infants

NCT05436184
View directory record Official record
Conditions
Influenza
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Not applicable Interventional

Opting In vs Opting Out

NCT01233804
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Opting Out
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 31, 2018 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 4 Interventional Results available

High Dose Influenza Vaccine in Nursing Home - Pilot Study

NCT01720277
View directory record Official record
Conditions
Influenza
Interventions
HD Fluzone Vaccine, SD Fluzone Vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
2,957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Providence, Rhode Island • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2018 · Synced Oct 15, 2026, 1:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults

NCT03186781
View directory record Official record
Conditions
Influenza
Interventions
VRC-FLUNPF081-00-VP (HA-F A/Sing), VRC-FLUDNA082-00-VP (DNA A/Sing)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 15, 2026, 1:16 AM EDT